 Unique avidity driven mechanism engages CD3 on T cells when binding either two or three tumor-associated antigens to enhance selectivity for AML cells Preclinical data demonstrated that MP0533 can selectively target and kill both leukemic blast cells and stem cells, while sparing healthy cells ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 16, 2023 GLOBE NEWSWIRE ... The post Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloi... 